Omada Health's First Quarter Results: Testing Whether Last Year's Profitability Was a Turning Point

Omada Health (OMDA) reports first quarter 2026 earnings after market close on May 7, 2026, with investors focused on whether the virtual healthcare provider can sustain the profitability momentum that marked its breakthrough fourth quarter of 2025. The company's ability to balance rapid member growth—particularly in its GLP-1 companion programs—with continued margin expansion will be central to the investment thesis as OMDA navigates a pivotal year of scaling its multi-condition platform.

Part 1: Earnings Preview

Omada Health operates as a virtual between-visit healthcare provider, delivering personalized care for chronic conditions including obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions through a combination of human-led care teams, connected devices, and AI-enabled technology. The company has emerged as a leader in GLP-1 companion support, having served more than 150,000 members on GLP-1 medications as of year-end 2025.

OMDA is expected to report first quarter 2026 results after the close on May 7, with consensus calling for an EPS loss of -$0.08 on two analyst estimates (ranging from -$0.11 to -$0.05). The most recently reported quarter—Q4 2025—delivered actual EPS of $0.08, marking the company's first profitable quarter and significantly exceeding the -$0.04 estimate. Year-over-year comparisons are not available as the company was not yet public in Q1 2025, but the sequential trajectory from profitability in Q4 back to an expected loss in Q1 reflects typical seasonality in healthcare enrollment and engagement patterns.

Three key themes define this earnings story:

GLP-1 Program Momentum and Prescribing Expansion: Omada's leadership in GLP-1 companion care represents both a growth driver and a proof point for its virtual care model. The company announced plans to launch a prescribing offering combining medication management with behavior change programs, and in early 2026 introduced GLP-1 Flex Care—a structured pathway for employers to provide clinical evaluation and prescribing without directly covering GLP-1 costs. Investors will watch for member growth in GLP-1 programs and early traction from these new offerings, which could significantly expand Omada's addressable market and revenue per member.

Profitability Sustainability and Margin Trajectory: After achieving positive net income in Q4 2025 and full-year adjusted EBITDA of $6 million (versus a $29 million loss in 2024), the critical question is whether Omada can maintain its margin gains while continuing to invest in growth. The company's gross margin expanded to 71% in Q4 from 67% a year earlier, driven by operating leverage as the member base scaled 55% year-over-year to 886,000. Management's 2026 guidance calls for $7-15 million in adjusted EBITDA on $312-322 million in revenue (22% growth at midpoint), suggesting continued profitability improvement but with quarterly variability.

Multi-Condition Platform Expansion: Omada's February 2026 launch of Omada for Cholesterol—addressing a highly prevalent condition that often co-exists with diabetes, hypertension, and obesity—signals the company's strategy to deepen engagement and increase revenue per customer by serving multiple conditions within its existing member base. The expansion builds on 2025 innovations including AI-powered tools like OmadaSpark and Meal Map, which support members alongside human coaches. Investors will look for evidence that these program additions are driving higher attach rates and improved member outcomes.

Analyst commentary ahead of the release has been constructive, with the consensus recommendation improving to 4.38 (between Buy and Strong Buy) from 4.33 a month ago, and eight of 13 analysts now rating the stock a Strong Buy. The average price target of $21.42 implies 35% upside from current levels, reflecting optimism about Omada's ability to capitalize on the intersection of virtual care delivery, chronic disease management, and the GLP-1 therapy wave.

Part 2: Historical Earnings Performance

Omada Health has demonstrated a clear pattern of exceeding expectations since going public, with the company beating EPS estimates in two of its three reported quarters as a public company. In Q2 2025 (June), OMDA reported a loss of -$0.22 versus the -$0.15 estimate, missing by 46.67% in what proved to be an investment period as the company scaled its GLP-1 programs and expanded its care team infrastructure. The trajectory improved dramatically in the subsequent quarters: Q3 2025 (September) delivered -$0.03 against a -$0.24 estimate for an 87.50% beat, and Q4 2025 (December) posted $0.08 versus a -$0.04 estimate—a 300% beat that marked the company's first profitable quarter.

The progression reveals a business model reaching inflection as operating leverage takes hold. The magnitude of beats has accelerated from 87.50% in Q3 to 300% in Q4, suggesting Omada's margin expansion is outpacing analyst models. The Q2 miss now appears to have been a deliberate investment trough, with the company prioritizing member growth and program development ahead of the profitability inflection that materialized in the second half of 2025. With Q1 2026 estimates calling for a return to a modest loss of -$0.08, investors will be watching whether the company can beat expectations for a third consecutive quarter and demonstrate that Q4's profitability was not an anomaly but rather the beginning of a sustainable trend.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Omada Health reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price behavior shows OMDA exhibits moderate volatility around earnings, with an average absolute Day 0 move of 2.28% and Day 0 range of 7.89%, expanding to an average absolute Day +1 move of 4.23% and Day +1 range of 14.44% as the market fully processes results. The most recent earnings on March 5, 2026 saw relatively muted initial reaction with a Day 0 move of just 0.59%, but Day +1 delivered a 3.31% gain as investors absorbed the significance of the company's first profitable quarter. The largest post-earnings move came after the November 2025 report, which saw a -7.13% Day +1 decline despite the company beating estimates, likely reflecting concerns about the Q2 miss and uncertainty about the path to profitability. The pattern suggests OMDA's post-earnings moves are more driven by forward guidance and margin trajectory than by the beat/miss itself, with the Day +1 session typically providing the more meaningful directional signal.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.43% expected move through the May 15 expiration (9 days out), which sits between the historical Day 0 average of 2.28% and the Day +1 average of 4.23%, but well below the average Day +1 range of 14.44%. This suggests options traders may be underpricing potential volatility relative to OMDA's recent earnings history, particularly given the heightened focus on whether the company can sustain its Q4 profitability breakthrough.

Part 3: What Analysts Are Saying

Analyst sentiment on Omada Health is decidedly bullish heading into the Q1 report, with a consensus rating of 4.38 (between Buy and Strong Buy) and an average price target of $21.42—implying 35% upside from the current price of $15.86. The rating breakdown shows strong conviction: 8 Strong Buys, 2 Moderate Buys, and 3 Holds, with no sell ratings. Sentiment has improved over the past month, with one analyst upgrading to Strong Buy, bringing the total from 7 to 8.

The price target range spans from $14.00 to $30.00, reflecting divergent views on how quickly Omada can scale its GLP-1 programs and sustain profitability. Bulls at the high end of the range appear to be modeling aggressive member growth and margin expansion as the company's virtual care model demonstrates operating leverage, while more conservative analysts near the low end likely await multiple quarters of consistent profitability before assigning a premium valuation. The clustering of Strong Buy ratings suggests the analyst community views the current price as an attractive entry point, particularly given the company's transition from cash-burn mode to positive adjusted EBITDA and the significant market opportunity in virtual chronic disease management and GLP-1 companion care.

Part 4: Technical Picture

Omada Health enters earnings with improving technical momentum, though still trading below its longer-term trend. The Barchart Technical Opinion currently shows a Sell signal at 8%, representing a significant improvement from 24% Sell a week ago and 80% Sell a month ago, indicating a sharp reversal in near-term momentum as the stock has rallied into the earnings release.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal reflects positive near-term momentum as the stock has pushed above multiple moving averages
• Medium-term (50% Sell): Neutral-to-negative reading suggests the intermediate trend remains uncertain despite recent gains
• Long-term (50% Sell): Moderate sell signal indicates the longer-term trend has not yet turned decisively positive

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting the recent rally lacks strong conviction and remains vulnerable to reversal if earnings disappoint.

The stock is trading at $15.86, positioned above its 5-day ($15.42), 10-day ($14.91), 20-day ($14.03), 50-day ($13.59), and 100-day ($13.99) moving averages, but remains below the critical 200-day moving average at $17.72. This setup shows OMDA has built short-term momentum coming off its Q4 profitability surprise, successfully reclaiming all key short- and intermediate-term moving averages. However, the failure to recapture the 200-day average—which has served as resistance—suggests the stock needs a strong earnings beat and confident guidance to break through to a sustained uptrend.

The 200-day moving average at $17.72 represents the key technical hurdle, sitting 12% above current levels and likely serving as initial resistance on any post-earnings rally. Support appears well-established in the $13.50-$14.00 zone where the 20-day, 50-day, and 100-day averages have converged. The technical setup is cautiously supportive heading into earnings: the stock has momentum and reclaimed support, but the weak trend characteristics and proximity to resistance suggest limited room for error if results or guidance fall short of expectations.